Oryzon Genomics SA
MAD:ORY

Watchlist Manager
Oryzon Genomics SA Logo
Oryzon Genomics SA
MAD:ORY
Watchlist
Price: 2.915 EUR -3.16% Market Closed
Market Cap: 232.9m EUR

Relative Value

There is not enough data to reliably calculate the relative value of ORY.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ORY Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.9
Forward
43.7
vs History
vs Industry
Median 3Y
-33.1
Median 5Y
-34.7
Industry
23.7
Forward
-78.2
vs History
vs Industry
Median 3Y
-65.2
Median 5Y
-184.6
Industry
22
vs History
vs Industry
Median 3Y
-20.5
Median 5Y
-36.1
Industry
23.8
vs History
26
vs Industry
38
Median 3Y
1.5
Median 5Y
1.6
Industry
3.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.3
Forward
37.8
vs History
vs Industry
Median 3Y
-92.3
Median 5Y
-104.5
Industry
10.1
vs History
vs Industry
Median 3Y
-25.1
Median 5Y
-25.8
Industry
6.4
Forward
-42.6
vs History
vs Industry
Median 3Y
-24.3
Median 5Y
-24.9
Industry
7
Forward
-27.7
vs History
vs Industry
Median 3Y
-60.4
Median 5Y
-177
Industry
8.3
vs History
vs Industry
Median 3Y
-7.9
Median 5Y
-17.4
Industry
6.5
vs History
22
vs Industry
47
Median 3Y
1.3
Median 5Y
1.3
Industry
5.7

Multiples Across Competitors

ORY Competitors Multiples
Oryzon Genomics SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
ES
Oryzon Genomics SA
MAD:ORY
226m EUR 0 -85.2 -40.6 -39.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 786 100.8 -160 580.3 -194 995.7 -192 770.6
US
Abbvie Inc
NYSE:ABBV
398.1B USD 6.7 169.5 16.4 23.3
US
Amgen Inc
NASDAQ:AMGN
174.6B USD 4.9 24.9 18 18
US
Gilead Sciences Inc
NASDAQ:GILD
151.1B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.8B USD 9.7 31 22.7 23.7
US
Epizyme Inc
F:EPE
94.1B EUR 2 085.2 -532.1 -579.4 -563.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD 5.6 17.3 16.5 18.6
AU
CSL Ltd
ASX:CSL
84.2B AUD 3.6 18.5 12.5 15.6
NL
argenx SE
XBRU:ARGX
45B EUR 14.7 34.5 59.5 61.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.4B USD 16.3 1 203.2 158 191.7
P/S Multiple
Revenue Growth P/S to Growth
ES
Oryzon Genomics SA
MAD:ORY
Average P/S: 3 378 825.3
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 786 100.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.7
10%
1
US
E
Epizyme Inc
F:EPE
2 085.2
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
NL
argenx SE
XBRU:ARGX
14.7
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.3
46%
0.4
P/E Multiple
Earnings Growth PEG
ES
Oryzon Genomics SA
MAD:ORY
Average P/E: 189.7
Negative Multiple: -85.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 580.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
169.5
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
9%
1.9
AU
CSL Ltd
ASX:CSL
18.5
11%
1.7
NL
argenx SE
XBRU:ARGX
34.5
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 203.2
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ES
Oryzon Genomics SA
MAD:ORY
Average EV/EBITDA: 39.5
Negative Multiple: -40.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 995.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.4
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.7
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
11%
1.5
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
NL
argenx SE
XBRU:ARGX
59.5
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
158
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ES
Oryzon Genomics SA
MAD:ORY
Average EV/EBIT: 45.6
Negative Multiple: -39.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 770.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.3
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.7
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.6
13%
1.4
AU
CSL Ltd
ASX:CSL
15.6
11%
1.4
NL
argenx SE
XBRU:ARGX
61.1
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
191.7
N/A N/A